Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $29.0909.

Several equities research analysts have weighed in on ELAN shares. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. UBS Group boosted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th.

Elanco Animal Health Trading Down 2.8%

Elanco Animal Health stock opened at $22.10 on Friday. The firm’s 50-day moving average is $24.60 and its 200-day moving average is $24.04. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health has a 1 year low of $17.11 and a 1 year high of $27.98. The company has a market cap of $11.04 billion, a P/E ratio of -53.90, a PEG ratio of 1.36 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the business posted $0.26 EPS. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts expect that Elanco Animal Health will post 1.12 earnings per share for the current year.

Insider Activity

In other news, Director Paul Herendeen purchased 10,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were bought at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the purchase, the director owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 24,082 shares of company stock worth $533,542 in the last quarter. Company insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

Several large investors have recently added to or reduced their stakes in ELAN. Elevation Point Wealth Partners LLC acquired a new position in Elanco Animal Health during the 2nd quarter worth $223,000. Commerce Bank acquired a new position in shares of Elanco Animal Health during the second quarter valued at $926,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Elanco Animal Health during the second quarter valued at about $270,000. Quantbot Technologies LP bought a new stake in shares of Elanco Animal Health during the second quarter valued at about $272,000. Finally, Evolve Private Wealth LLC bought a new stake in shares of Elanco Animal Health during the second quarter valued at about $708,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.